|
 The new drugs, which have not been detailed to
investors, will include cancer and respiratory disease medicines,
the newspaper said on its website. (http://link.reuters.com/fup56v)
Britain's biggest drugmaker is also expected to report that
fourth-quarter sales in China, where it is embroiled in a major
bribery probe, took a smaller hit than when the scandal first blew
up during the summer quarter, the report said.
The investigation began in July 2013, after Chinese police accused
GSK of funneling up to 3 billion yuan ($495.05 million) to travel
agencies to facilitate bribes to boost its drug sales. ($1 = 6.0600
Chinese yuan)
(Reporting by Richa Naidu in Bangalore;
editing by Dan Grebler)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
